Pharmacyte Biotech Stock Probability of Future Stock Price Finishing Under 1.83
| PMCB Stock | USD 1.50 0.08 5.06% |
PharmaCyte |
PharmaCyte Biotech Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of PharmaCyte Biotech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for PharmaCyte Biotech can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| PharmaCyte Biotech generated a negative expected return over the last 90 days | |
| PharmaCyte Biotech may become a speculative penny stock | |
| PharmaCyte Biotech has high historical volatility and very poor performance | |
| PharmaCyte Biotech has high likelihood to experience some financial distress in the next 2 years | |
| PharmaCyte Biotech currently holds about 82.23 M in cash with (2.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| PharmaCyte Biotech has a poor financial position based on the latest SEC disclosures |
PharmaCyte Biotech Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of PharmaCyte Stock often depends not only on the future outlook of the current and potential PharmaCyte Biotech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. PharmaCyte Biotech's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 9.6 M | |
| Cash And Short Term Investments | 50.2 M |
PharmaCyte Biotech Technical Analysis
PharmaCyte Biotech's future price can be derived by breaking down and analyzing its technical indicators over time. PharmaCyte Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of PharmaCyte Biotech. In general, you should focus on analyzing PharmaCyte Stock price patterns and their correlations with different microeconomic environments and drivers.
PharmaCyte Biotech Predictive Forecast Models
PharmaCyte Biotech's time-series forecasting models is one of many PharmaCyte Biotech's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary PharmaCyte Biotech's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about PharmaCyte Biotech
Checking the ongoing alerts about PharmaCyte Biotech for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for PharmaCyte Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| PharmaCyte Biotech generated a negative expected return over the last 90 days | |
| PharmaCyte Biotech may become a speculative penny stock | |
| PharmaCyte Biotech has high historical volatility and very poor performance | |
| PharmaCyte Biotech has high likelihood to experience some financial distress in the next 2 years | |
| PharmaCyte Biotech currently holds about 82.23 M in cash with (2.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| PharmaCyte Biotech has a poor financial position based on the latest SEC disclosures |
Check out PharmaCyte Biotech Backtesting, PharmaCyte Biotech Valuation, PharmaCyte Biotech Correlation, PharmaCyte Biotech Hype Analysis, PharmaCyte Biotech Volatility, PharmaCyte Biotech History as well as PharmaCyte Biotech Performance. For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PharmaCyte Biotech. If investors know PharmaCyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PharmaCyte Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of PharmaCyte Biotech is measured differently than its book value, which is the value of PharmaCyte that is recorded on the company's balance sheet. Investors also form their own opinion of PharmaCyte Biotech's value that differs from its market value or its book value, called intrinsic value, which is PharmaCyte Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PharmaCyte Biotech's market value can be influenced by many factors that don't directly affect PharmaCyte Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PharmaCyte Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if PharmaCyte Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PharmaCyte Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.